We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-7.42%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
-$263M
Cap. Flow
-$30.3M
Cap. Flow %
-2.33%
Top 10 Hldgs %
46.95%
Holding
119
New
12
Increased
27
Reduced
37
Closed
33
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
1 year
Avg Time Held Equity only
1 year
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$41.1M
2
MASI icon
Masimo
MASI
+$40.1M
3
GSK icon
GSK
GSK
+$30.1M
4
HCA icon
HCA Healthcare
HCA
+$15.7M
5
RCM icon
R1 RCM Inc. Common Stock
RCM
+$15.4M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$22.8M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$21.8M
3
UTHR icon
United Therapeutics
UTHR
+$19M
4
NVST icon
Envista
NVST
+$12.9M
5
HUM icon
Humana
HUM
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 78.97%
2 Miscellaneous 18.23%
3 Industrials 2.8%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MYO icon
101
Myomo
MYO
$47.5M
– –
-150,000
Closed -$1.03M –
NTRA icon
102
Natera
NTRA
$56.7B
– –
-102,071
Closed -$9.53M –
PODD icon
103
Insulet
PODD
$9.79B
– –
-30,172
Closed -$8.03M –
SIBN icon
104
SI-BONE Inc
SIBN
$882M
– –
-258,094
Closed -$5.73M –
SNY icon
105
Sanofi
SNY
$97.3B
– –
-38,672
Closed -$1.94M –
UTHR icon
106
CALL
United Therapeutics
UTHR
$22.9B
– –
-7,600
Closed -$1.64M –
VRTX icon
107
CALL
Vertex Pharmaceuticals
VRTX
$127B
– –
-94,100
Closed -$20.7M –
XBI icon
108
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.54B
– –
-113,800
Closed -$12.7M –
NVRO icon
109
DELISTED
NEVRO CORP.
NVRO
– –
-66,074
Closed -$5.36M –
ITCI icon
110
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-231,787
Closed -$12.1M –
GRTS icon
111
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-170,125
Closed -$2.19M –
MRTX
112
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-14,840
Closed -$2.18M –
FSTX
113
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-49,933
Closed -$251K –
LOGC
114
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
– –
-291,101
Closed -$672K –
CERN
115
DELISTED
Cerner Corp
CERN
– –
-77,543
Closed -$7.22M –
VCRA
116
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
– –
-14,970
Closed -$971K –
MGLN
117
DELISTED
Magellan Health Services, Inc.
MGLN
– –
-104,700
Closed -$9.95M –
HZNP
118
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-70,000
Closed -$7.54M –
ZGNX
119
DELISTED
Zogenix, Inc.
ZGNX
– –
-550,966
Closed -$8.95M –
1 2 3 4
5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2022 Portfolio in Review

As of Q1 2022, Eversept Partners held 119 positions worth $1.3B, down 17% from $1.57B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners's Q1 2022 filing shows 12 new, 27 increased, 37 reduced and 33 closed positions. Its largest new stake was Masimo: 208,970 shares worth $30.4M. The largest sale was McKesson, an estimated $22.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 72% a quarter earlier, followed by Miscellaneous and Industrials.

  • Eversept Partners's largest Q1 2022 buy was Masimo: 208,970 shares worth $30.4M.
  • Eversept Partners added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2022, an estimated $41.1M increase.
  • Eversept Partners's biggest Q1 2022 reduction was McKesson, cutting an estimated $22.8M.
  • Eversept Partners fully exited Humana in Q1 2022, selling an estimated $12.7M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.3B portfolio in Q1 2022.
  • Eversept Partners opened 12 new positions and closed 33 in Q1 2022.
  • Eversept Partners's portfolio value fell 17% quarter-over-quarter to $1.3B.

Based on Eversept Partners's 13F filing for Q1 2022, filed 16 May 2022.